One-Time DNA Study for Vasculitis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.
| Condition |
|---|
|
Churg-Strauss Syndrome Giant Cell Arteritis Granulomatosis With Polyangiitis (Wegener's) Microscopic Polyangiitis Polyarteritis Nodosa Takayasu's Arteritis |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | VCRC Genetic Repository One-Time DNA Protocol |
- Evaluation of clinical data and linked DNA specimens. [ Time Frame: 1 year. ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Two 10 ml tubes of blood will be collected for DNA extraction.
| Estimated Enrollment: | 1300 |
| Study Start Date: | October 2010 |
| Estimated Study Completion Date: | August 2014 |
| Estimated Primary Completion Date: | August 2014 (Final data collection date for primary outcome measure) |
The systemic vasculitides comprise several inflammatory diseases of blood vessels, usually arteries, which may cause systemic, multi-organ disease that can result in substantial morbidity and increased mortality. Each type of vasculitis is a rare ("orphan") disease. However, taken together, vasculitis affects tens of thousands of Americans and is responsible for substantial morbidity and mortality and almost one billion dollars per year in hospital care alone. While the vasculitides share the trait of vascular inflammation, the unique disease phenotypes, clinical courses, differences in prognoses, and responses to therapy suggest that important differences exist in pathogenesis. The Vasculitis Clinical Research Consortium (VCRC) currently focuses on 6 specific types of vasculitis that were selected to represent a balance between unmet medical and scientific needs, prevalence in North America, feasibility of study, and an interest in studying a spectrum of small, medium, and large vessel vasculitides.
The great majority of published studies on the genetics of vasculitis have used modest-sized cohorts that are only suitable for investigation of a few candidate genes at a time, or to detect large effect sizes, so that replicated findings are highly skewed to the HLA region. Larger and more ambitious genetic studies in vasculitis are expected to generate numerous hypotheses for translational research in gene expression, biochemistry, and molecular pathology.
A one-time collection of clinical data and DNA would substantially increase the sample sizes for genetic association studies in all six vasculitides studied in the VCRC. Many patients are seen at participating VCRC centers but do not enroll in the Longitudinal Studies. These patients often are interested in participating in research studies but cannot return frequently for visits, usually due to distance from the VCRC centers. This approach would be particularly useful for the rarer forms of vasculitis under study (Takayasu's Arteritis (TAK), Polyarteritis Nodosa (PAN), Churg-Strauss Syndrome (CSS) and also for Giant Cell Arteritis (GCA), since elderly patients have been particularly likely to decline participation in the Longitudinal Studies due to travel constraints.
Eligibility| Ages Eligible for Study: | 7 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Individuals with giant cell arteritis, Takayasu's arteritis, polyarteritis nodosa, granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, and Churg-Strauss syndrome. Enrollment will be sequential and patients will have disease in various stages and of different duration.
Inclusion Criteria:
1. Diagnostic criteria for Giant Cell Arteritis Age at disease onset >50 years (required)
- New onset or new type of localized pain in the head
- Temporal artery abnormality (i.e. temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries)
- ESR of >40mm in the first hour by the Westergren method
- Abnormal artery biopsy (i.e. temporal artery biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells)
- Large Vessel Vasculitis (LVV) by angiogram or biopsy not explained by something else
2. Diagnostic criteria for Takayasu's Arteritis
- Age at disease onset <50 years
- Claudication of extremities
- Decreased brachial artery pulse (one or both arteries)
- Blood pressure difference of >10mm Hg between the arms
- Bruit over subclavian arteries or aorta
- Arteriogram abnormalities compatible with TAK (includes conventional dye angiography or MR angiography or CT angiography)
3. Diagnostic criteria for Polyarteritis Nodosa Major criteria (not explained by other causes) felt by investigator to be due to vasculitis
- Arteriographic abnormality
- Presence of granulocyte or mixed leukocyte infiltrate in an arterial wall on biopsy
- Mononeuropathy or polyneuropathy
Minor criteria (not explained by other causes) felt by investigator to be due to vasculitis
- Weight loss > 4 kg
- Livedo reticularis, cutaneous ulcerations, or skin nodules
- Testicular pain or tenderness
- Myalgias
- Diastolic blood pressure > 90 mm Hg
- Elevated BUN or serum creatinine levels
- Ischemic abdominal pain
Isolated cutaneous Polyarteritis Nodosa 1. Biopsy-proven cutaneous PAN
4. Diagnostic criteria for Granulomatosis with Polyangiitis (Wegener's) (GPA) and Microscopic Polyangitis (MPA)
- Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to classification criteria or definitions, have not been developed for GPA & MPA.
For diagnosis of GPA meets at least 2 of the following 5 modified ACR criteria:
- Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood
- Abnormal chest radiograph with nodules, fixed infiltrates, or cavities
- Urinary sediment with microhematuria or red cell casts
- Granulomatous inflammation within the wall of an artery or in the perivascular area on biopsy
- Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for either PR3- or MPO-ANCA
For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA:
- Necrotizing vasculitis, with few or no immune deposits, that affects small vessels (i.e., capillaries, venules, arterioles)
- Necrotizing arteritis involving small- and medium-sized arteries may be present
- Necrotizing glomerulonephritis is very common
Pulmonary capillaritis often occurs
5. Diagnostic criteria for Churg-Strauss Syndrome
- Asthma
- Peak peripheral blood eosinophilia of >10% of total WBC
- Peripheral neuropathy attributable to vasculitis
- Transient pulmonary infiltrates on chest imaging studies
- Paranasal sinus abnormalities or nasal polyposis
- Eosinophilic inflammation on tissue biopsy
If patients have 4 of the above 6 criteria but lack clearcut documentation of small vessel vasculitis, they are also eligible for enrollment.
General Exclusion Criteria:
- Inability to give informed consent and to sign the consent form
- Enrolled in VCRC protocols 5502, 5503, 5504, 5505, 5506, 5522, or 5523
- Unwilling to provide blood for DNA collection
Contacts and Locations| Contact: Carol McAlear, MA | cmcalear@upenn.edu |
| United States, California | |
| Cedars-Sinai Medical Center | Recruiting |
| Los Angeles, California, United States, 90048 | |
| Contact: Denise Salinas denise.salinas@cshs.org | |
| Principal Investigator: Michael Weisman, MD | |
| University of California, San Francisco | Recruiting |
| San Francisco, California, United States, 94143 | |
| Contact: Ruby Harrison rubyh@medicine.ucsf.edu; | |
| Principal Investigator: Sharon Chung, MD, MAS | |
| United States, Maryland | |
| Johns Hopkins Medical Center | Active, not recruiting |
| Baltimore, Maryland, United States, 21224 | |
| United States, Massachusetts | |
| Boston University School of Medicine | Recruiting |
| Boston, Massachusetts, United States, 02118 | |
| Contact: Daniel Finkel 617-414-2509 | |
| Principal Investigator: Paul Monach, MD, PhD | |
| United States, Minnesota | |
| Mayo Clinic | Recruiting |
| Rochester, Minnesota, United States, 55905 | |
| Contact: Sara Biorn 507-284-4862 biorn.sara@mayo.edu | |
| Contact: Jane Jaquith 507-284-4502 jaquith.jane@mayo.edu | |
| Principal Investigator: Ulrich Specks, MD | |
| Principal Investigator: Steven Ytterberg, MD | |
| United States, New York | |
| Hospital for Special Surgery | Recruiting |
| New York, New York, United States, 10021 | |
| Contact: Uzunma Udeh udehu@hss.edu | |
| Principal Investigator: Robert Spiera, MD | |
| United States, Ohio | |
| Cleveland Clinic | Recruiting |
| Cleveland, Ohio, United States, 44195 | |
| Contact: Katie Gartner 216-445-1397 gartnek@ccf.org | |
| Principal Investigator: Carol Langford, MD, MHS | |
| United States, Pennsylvania | |
| University of Pennsylvania | Recruiting |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Contact: Alex Giardino alexandra.giardino@uphs.upenn.edu | |
| Principal Investigator: Peter Merkel, MD, MPH | |
| Canada, Ontario | |
| St. Joseph's Healthcare | Recruiting |
| Hamilton, Ontario, Canada | |
| Contact: Sandra Messier 905-522-1155 ext 35873 smessier@stjoes.ca | |
| Principal Investigator: Nader Khalidi, MD | |
| Mount Sinai Hospital | Recruiting |
| Toronto, Ontario, Canada, M5T 3L9 | |
| Contact: Julia Farquharson 416-586-8616 JFarquharson@mtsinai.on.ca | |
| Principal Investigator: Simon Carette, MD | |
| Principal Investigator: | Peter A Merkel, MD, MPH | University of Pennsylvania |
| Principal Investigator: | Paul A Monach, MD, PhD | Boston University |
| Principal Investigator: | Carol Langford, MD, MHS | The Cleveland Clinic |
| Principal Investigator: | Phil Seo, MD, MHS | Johns Hopkins University |
| Principal Investigator: | Ulrich Specks, MD | Mayo Clinic |
| Principal Investigator: | Steven Ytterberg, MD | Mayo Clinic |
| Principal Investigator: | Simon Carette, MD | Mount Sinai Hospital/University of Toronto |
| Principal Investigator: | Nader Khalidi, MD | St. Joseph's Hospital/McMaster University |
| Principal Investigator: | Larry Moreland, MD | University of Pittsburgh |
| Principal Investigator: | Curry Koening, MD, MS | University of Utah |
More Information
Additional Information:
No publications provided
| Responsible Party: | Peter Merkel, Professor, University of Pennsylvania |
| ClinicalTrials.gov Identifier: | NCT01241305 History of Changes |
| Other Study ID Numbers: | RDCRN 5510, U54AR057319-06 |
| Study First Received: | October 22, 2010 |
| Last Updated: | October 23, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Pennsylvania:
|
Vasculitis |
Additional relevant MeSH terms:
|
Vasculitis Systemic Vasculitis Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Vasculitis, Central Nervous System Arteritis Churg-Strauss Syndrome Polyarteritis Nodosa Takayasu Arteritis Aortic Arch Syndromes Giant Cell Arteritis Polymyalgia Rheumatica Wegener Granulomatosis Microscopic Polyangiitis Vascular Diseases Cardiovascular Diseases |
Granuloma Lymphoproliferative Disorders Lymphatic Diseases Autoimmune Diseases Immune System Diseases Skin Diseases, Vascular Skin Diseases Aortic Diseases Autoimmune Diseases of the Nervous System Nervous System Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Muscular Diseases Musculoskeletal Diseases |
ClinicalTrials.gov processed this record on June 18, 2013